Lexicon Pharmaceuticals, Inc. (LXRX): Price and Financial Metrics
GET POWR RATINGS... FREE!
LXRX POWR Grades
- LXRX scores best on the Sentiment dimension, with a Sentiment rank ahead of 82.85% of US stocks.
- LXRX's strongest trending metric is Growth; it's been moving up over the last 179 days.
- LXRX ranks lowest in Momentum; there it ranks in the 4th percentile.
LXRX Stock Summary
- The capital turnover (annual revenue relative to shareholder's equity) for LXRX is 0 -- better than only 6.99% of US stocks.
- LXRX's price/sales ratio is 3,049.81; that's higher than the P/S ratio of 99.82% of US stocks.
- Revenue growth over the past 12 months for LEXICON PHARMACEUTICALS INC comes in at -74.12%, a number that bests just 2.26% of the US stocks we're tracking.
- Stocks that are quantitatively similar to LXRX, based on their financial statements, market capitalization, and price volatility, are SPCE, PXLW, CDXS, MRNS, and CLGN.
- Visit LXRX's SEC page to see the company's official filings. To visit the company's web site, go to www.lexpharma.com.
LXRX Valuation Summary
- In comparison to the median Healthcare stock, LXRX's price/sales ratio is 66900% higher, now standing at 3216.
- Over the past 243 months, LXRX's price/sales ratio has gone up 3210.6.
Below are key valuation metrics over time for LXRX.
| Stock | Date | P/S | P/B | P/E | EV/EBIT |
|---|---|---|---|---|---|
| LXRX | 2022-11-25 | 3216.0 | 2.8 | -4.1 | -4.3 |
| LXRX | 2022-11-23 | 3216.0 | 2.8 | -4.1 | -4.3 |
| LXRX | 2022-11-22 | 3352.0 | 2.9 | -4.3 | -4.5 |
| LXRX | 2022-11-21 | 3306.4 | 2.9 | -4.3 | -4.4 |
| LXRX | 2022-11-18 | 3352.0 | 2.9 | -4.3 | -4.5 |
| LXRX | 2022-11-17 | 3336.8 | 2.9 | -4.3 | -4.4 |
LXRX Growth Metrics
- Its year over year price growth rate is now at -58.52%.
- Its 3 year net income to common stockholders growth rate is now at 9.97%.
- Its 3 year cash and equivalents growth rate is now at 30.02%.
The table below shows LXRX's growth in key financial areas (numbers in millions of US dollars).
| Date | Revenue | Operating Cash Flow | Net Income to Common Stock |
|---|---|---|---|
| 2022-09-30 | 0.125 | -90.11 | -97.061 |
| 2022-06-30 | 0.109 | -87.821 | -96.796 |
| 2022-03-31 | 0.308 | -85.279 | -90.276 |
| 2021-12-31 | 0.298 | -87.017 | -87.758 |
| 2021-09-30 | 0.483 | -98.428 | -67.642 |
| 2021-06-30 | 7.094 | -121.656 | 38.083 |
LXRX's Quality Factors
The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.- LXRX has a Quality Grade of D, ranking ahead of 14.8% of graded US stocks.
- LXRX's asset turnover comes in at 0.038 -- ranking 340th of 681 Pharmaceutical Products stocks.
- SEEL, AVEO, and OTLK are the stocks whose asset turnover ratios are most correlated with LXRX.
The table below shows LXRX's key quality metrics over time.
| Period | Asset Turnover | Gross Margin | ROIC |
|---|---|---|---|
| 2021-06-30 | 0.038 | 0.911 | 2.792 |
| 2021-03-31 | 0.071 | 0.915 | -0.037 |
| 2020-12-31 | 0.089 | 0.920 | -0.233 |
| 2020-09-30 | 0.101 | 0.917 | -0.269 |
| 2020-06-30 | 0.824 | 0.992 | 0.131 |
| 2020-03-31 | 0.875 | 0.990 | 0.239 |
LXRX Price Target
For more insight on analysts targets of LXRX, see our LXRX price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.
| Average Price Target | $12.50 | Average Broker Recommendation | 1.67 (Moderate Buy) |
LXRX Stock Price Chart Interactive Chart >
LXRX Price/Volume Stats
| Current price | $2.26 | 52-week high | $4.72 |
| Prev. close | $2.14 | 52-week low | $1.31 |
| Day low | $2.10 | Volume | 299,637 |
| Day high | $2.26 | Avg. volume | 874,398 |
| 50-day MA | $2.20 | Dividend yield | N/A |
| 200-day MA | $2.29 | Market Cap | 426.52M |
Lexicon Pharmaceuticals, Inc. (LXRX) Company Bio
Lexicon Pharmaceuticals is a biopharmaceutical company focused on developing breakthrough treatments for human disease. Lexicon has clinical-stage drug programs for diabetes and carcinoid syndrome in progress. The company was founded in 1995 and is based in The Woodlands, Texas.
Latest LXRX News From Around the Web
Below are the latest news stories about LEXICON PHARMACEUTICALS INC that investors may wish to consider to help them evaluate LXRX as an investment opportunity.
Lexicon Pharmaceuticals to Participate in the 34th Annual Piper Sandler Healthcare Conference and the 5th Annual Evercore ISI HealthCONx ConferenceTHE WOODLANDS, Texas, Nov. 28, 2022 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced its participation in the following investor conferences taking place November 29 - December 1, 2022: 34th Annual Piper Sandler Healthcare Conference5th Annual Evercore ISI HealthCONx Conference Lonnel Coats, Lexicon’s chief executive officer, Jeffrey L. Wade, Lexicon’s president and chief financial officer, and Craig Granowitz, M.D., Ph.D., Lexicon’s senior vice president and chie |
Lexicon's Experimental Drug Shows Significant, Consistent Benefits In Diabetic Neuropathy StudyLexicon Pharmaceuticals Inc (NASDAQ: LXRX) announced that full results from the RELIEF-DPN-1 trial of its investigational drug LX9211 were presented at the 16th Annual Pain Therapeutics Summit. The full data comes from the entire 11-week evaluation period, including a 5-week placebo run-off following the initial 6-week treatment period. The data exhibited consistent and statistically significant treatment-period benefits in measures of particular importance in painful diabetic neuropathy (also k |
Lexicon’s LX9211 Shows Significant and Consistent Benefits in the Treatment of Painful Diabetic Neuropathy in Full Results From the Phase 2 RELIEF-DPN-1 Trial Presented at the 16th Annual Pain Therapeutics SummitAchieved primary endpoint for reduction in average daily pain score (ADPS) at week 6Significant benefits demonstrated on burning pain and on pain interference with sleepNo evidence of withdrawal symptoms or rebound pain after treatment ended Conference Call and Webcast Today at 5:00pm ET Hosted by Lexicon Management THE WOODLANDS, Texas, Nov. 14, 2022 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that full results from the RELIEF-DPN-1 trial of its investigatio |
Lexicon Pharmaceuticals Third Quarter 2022 Earnings: EPS Beats Expectations, Revenues LagLexicon Pharmaceuticals ( NASDAQ:LXRX ) Third Quarter 2022 Results Key Financial Results Net loss: US$23.4m (loss... |
Lexicon Pharmaceuticals to Participate in the 13th Annual Jefferies London Healthcare ConferenceTHE WOODLANDS, Texas, Nov. 11, 2022 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced its participation in the 13th Annual Jefferies London Healthcare Conference, taking place November 15-17, 2022. Jeff Wade, Lexicon’s president and chief financial officer, will make a company presentation for the Jefferies conference which will be available on-demand beginning at 7:55 am ET/12:55 pm GMT on Wednesday, November 16, 2022. The webcast will be available in the “Events” |
LXRX Price Returns
| 1-mo | 7.11% |
| 3-mo | -16.91% |
| 6-mo | 24.86% |
| 1-year | -50.66% |
| 3-year | -31.52% |
| 5-year | -78.37% |
| YTD | -42.64% |
| 2021 | 15.20% |
| 2020 | -17.59% |
| 2019 | -37.50% |
| 2018 | -32.79% |
| 2017 | -28.56% |
Continue Researching LXRX
Want to do more research on Lexicon Pharmaceuticals Inc's stock and its price? Try the links below:Lexicon Pharmaceuticals Inc (LXRX) Stock Price | Nasdaq
Lexicon Pharmaceuticals Inc (LXRX) Stock Quote, History and News - Yahoo Finance
Lexicon Pharmaceuticals Inc (LXRX) Stock Price and Basic Information | MarketWatch
Loading social stream, please wait...